胰岛素降解酶基因多态性与多囊卵巢综合征相关性的研究

目的:探讨胰岛素降解酶基因(IDE)多态性与多囊卵巢综合征(PCOS)发病的关系。方法:用聚合酶链反应-限制性片段多态性技术,检测315例PCOS患者(PCOS组)和327例健康妇女(对照组)的IDE基因多态性。结果:IDE基因rs1887922位点基因型分布及等位基因频率在PCOS组总体以及各亚组(胰岛素抵抗组及非胰岛素抵抗组),与健康对照组之间比较均无显著差异。而IDE基因rs2209972位点基因型分布虽然在P- COS组总体及非胰岛素抵抗亚组与健康对照组之间比较无显著差异;但PCOS组总体相应位点的C等位基因频率高于对照组,差异有显著性(P<0.05),PCOS胰岛素抵抗亚组相应位点的基因型频率及等位基因频率均高于对照组,差异有统计学意义(P<0.05)。rs2209972位点不同基因型PCOS患者空腹胰岛素水平及HOMA-IR存在显著差异(P<0.05)。结论:胰岛素降解酶基因多态性可能与PCOS患者胰岛素抵抗相关。     

IDE基因和TCF7L2基因多态性与妊娠期糖尿病的相关性研究

目的探讨TCF7L2基因rs10885410、rs7100927位点和IDE基因rs10882066、rs11187007、rs7078413位点单核苷酸多态性(SNP)与妊娠期糖尿病(GDM)遗传易感性的关系。方法选取2011年9月至2013年8月在中国医科大学附属盛京医院住院分娩的GDM孕妇178例为病例组,同期121例葡萄糖耐量正常的妊娠妇女作为对照组。提取受试者全基因组DNA,对TCF7L2基因rs10885410、rs7100927位点和IDE基因rs10882066、rs11187007、rs7078413位点进行基因分型,并进行相关分析。结果 TCF7L2基因rs10885410、rs7100927位点各基因型和等位基因频率分布,两组间差异无统计学意义(P0.05)。IDE基因的rs11187007位点,病例组AA、AG、GG 3种基因型频率分别为4.49%、56.18%、39.33%,对照组分别为10.74%、38.84%、50.42%,两组比较,P0.05。AG基因型GDM的发病风险与AA基因型相比,OR值为3.457(95%CI 1.342~8.909,P=0.010),经Logistic回归校正混杂因素后,OR值为3.403(95%CI 1.072~10.803,P=0.038)。结论 IDE基因的rs11187007位点多态性可能与GDM遗传易感性有关;AG基因型可能是其发生的危险性因素。     

醛固酮合成酶基因多态性与多囊卵巢综合征相关性的研究

目的　探讨醛固酮合成酶 (CYP11B2 )基因多态性与多囊卵巢综合征 (PCOS)发病的关系。方法　采用聚合酶链反应、限制性内切酶消化及电泳技术 ,对 92例PCOS患者和 60例正常妇女的CYP11B2基因 3 44T位点基因多态性进行检测 ,并测定基础状态下促卵泡激素、促黄体生成素、雌二醇、睾酮、孕酮、泌乳素、血肾素活性、血管紧张素Ⅱ及醛固酮水平 ,比较不同基因型PCOS患者及正常妇女的肾素、血管紧张素、醛固酮及雄激素水平差异。结果　 ( 1)正常妇女、PCOS患者中 ,CYP11B2基因 3 44T位点C基因频率分别为 2 2 %和 3 6%。 ( 2 )PCOS患者T→C(TC、CC)出现率为 5 7% ,明显高于正常妇女的 3 7% (P <0 0 5 )。 ( 3 )PCOS患者CYP11B2基因型及基因频率的分布与正常妇女比较 ,差异有显著性 (P <0 0 5 ) ;CYP11B2基因 3 44TC、 3 44CC基因型的PCOS患者及正常妇女的肾素、血管紧张素、醛固酮及雄激素水平 ,均明显高于CYP11B2基因 3 44TT基因型者 (P <0 0 1)。结论　 ( 1)CYP11B2基因 3 44T位点变异 (T→C)的出现 ,可能增大了患PCOS的风险 ,并与PCOS发病有关。 ( 2 )CYP11B2基因 3 44CC、 3 44TC基因型可能是PCOS的易患基因型 ,并与PCOS患者肾素血管紧张素系统功能亢进有一定的关系     

一级亲属伴有代谢异常疾病的PCOS患者易感基因研究

目的:探讨基因单核苷酸多态性(SNP)与多囊卵巢综合征(PCOS)的相关性。方法:收集2018年1月至2019年12月就诊于新疆医科大学第一附属医院妇科的289例PCOS患者的临床资料。选取其中一级亲属患有代谢异常性疾病的35例PCOS患者和41例健康人群作为研究对象,采用Infinium Asian Screening BeadChip Array芯片检测全基因组SNP。通过KEGG富集分析和PPI分析确定易感基因和候选SNP位点,候选SNP位点进行群体遗传学分析。结果:芯片检测总差异SNP位点1141个(P≤0.001),生物信息学分析筛选出的易感基因和SNP位点为GNAO1(rs2587885),PIK3CD(rs6541017)和FGF13(rs527687、rs683357和rs7060413)。群体遗传学分析结果显示,rs527687位点A等位基因、rs683357位点G等位基因、rs6541017位点A等位基因、rs2587885位点C等位基因、rs7060413位点G等位基因在PCOS组中的频率显著低于对照组(P<0.05,OR<1且95%CI<1)。在共显性、显性、隐性遗传模型中rs527687、rs683357、rs6541017、rs2587885、rs7060413不同的基因型跟一级亲属有代谢性疾病的PCOS发病有相关性。结论:一级亲属患有代谢性疾病的PCOS患者rs2587885、rs6541017、rs527687、rs683357和rs7060413 SNP位点多态性与PCOS的发病风险具有相关性。     

间隙连接蛋白37(Cx37)rs1764391基因多态性与多囊卵巢综合征不孕患者辅助生殖技术结局的关系

目的分析连接蛋白37(Cx37)rs1764391基因多态性在多囊卵巢综合征(PCOS)患者中对控制性超促排卵的反应性及其妊娠结局的影响。方法选择经辅助生殖技术(ART)治疗的98例PCOS不孕女性,使用Taqman技术分析rs1764391基因多态性分布,随后评估rs1764391基因型、等位基因型对超促排卵的反应性以及ART妊娠结局的相关性。结果 PCOS患者组TT基因型、等位基因T的频率(18.4%,31.6%)显著高于正常组(9.6%,P=0.03;22.3%,P=0.04);LH浓度、窦卵泡数、h CG注射日雌激素水平、获卵数在基因型为TT的PCOS患者中要显著高于其它基因型(P0.05);此外,受精率在不同的rs1764391基因型间无统计学差异,而TT基因型患者的种植率(27.5%)与临床妊娠率(30.7%)显著低于CC、CT基因型患者(47.2%,52.3%,P=0.02;57.4%,69.6%,P=0.03);等位基因型T患者的临床妊娠率(45.1%)均显著低于C等位基因型(66.8%,P=0.04)。结论在PCOS不孕患者中Cx37 rs1764391基因多态性与ART结局密切相关。     

Vaspin基因多态性与多囊卵巢综合征的相关性

目的:研究Vaspin基因多态性与多囊卵巢综合征(PCOS)的关系。方法:选择2011年7月—2014年8月天津市中心妇产科医院确诊的PCOS患者200例为PCOS组,对照组选取非PCOS且无糖代谢异常的200例正常体检者。观察2组Vaspin rs2236242位点基因多态性基因频率的差别。结果:2组Vaspin rs2236242位点A等位基因与T等位基因频率比较,差异有统计学意义(OR=0.68,95%CI:0.51~0.91,P=0.009)。共显性遗传模型分析显示,TA基因型(OR=0.51,95%CI:0.33~0.79,P=0.002)和AA基因型者(OR=0.47,95%CI:0.23~0.95,P=0.035)的PCOS发病风险低于TT基因型者。显性遗传模型分析显示,TA+AA基因型者PCOS发病风险低于TT基因型者(OR=0.50,95%CI:0.33~0.77,P=0.001)。隐性遗传模型分析显示,AA基因型与TT+TA基因型者PCOS发病风险相似(OR=0.71,95%CI:0.37~1.38,P=0.317)。结论:Vaspin rs2236242位点基因多态性与PCOS发病有关,等位基因A及AA、TA基因型对PCOS发病可能起抑制作用。     

钙蛋白酶10基因多态性与多囊卵巢综合征患者糖耐量及脂代谢异常的相关性

目的 探讨钙蛋白酶10(CAPN-10)基因56位点单核苷酸多态性(SNP-56)与多囊卵巢综合征(PCOS)患者糖耐量及脂代谢异常的相关性.方法 选取山东地区PCOS患者334例(PCOS组),健康妇女304例(对照组),采用熔解温度不同的基因分型法检测CAPN-10基因SNP-56,并采用免疫化学发光法测定泌乳素、卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇、睾酮水平.PCOS组同时测定血糖、血脂、血清胰岛素水平.结果 (1)基因型及等位基因频率分布两组比较,差异均无统计学意义(P＞0.05).(2)在PCOS组,口服葡萄糖耐量试验(OGTF)180 min血糖水平AA基因型者为(5.7±2.2)mmol/L,GA基因型者为(4.9±1.2)mmol/L,GG基因型者为(4.9±1.4)mmol/L,分别比较,差异均有统计学意义(P均＜0.01);总胆固醇(TC)水平AA基因型者为(4.9±1.0)mmol/L,GA基因型者为(4.5±0.9)mmol/L,两者比较,差异也有统计学意义(P＜0.05).(3)在PCOS组,有糖尿病家族史者共44例,AA基因型频率为22.7%(10/44),GA+GG基因型频率为77.3%(34/44),GG基因型频率为34.1%(15/44);无糖尿病家族史者共290例,AA基因型频率为11.0%(32/290),GA+GG基因型频率为89.0%(258/290),GG基因型频率为47.2%(137/290),有无糖尿病家族史者AA与GA+GG基因型频率比较及AA与GG基因型频率比较,差异均有统计学意义(x2=4.751,x2=5.697;P均＜0.05).在PCOS组,有肿瘤家族史者共21例,AA基因型频率为33.3%(7/21),GA+GG基因型频率为66.7%(14/21),GG基因型频率为19.0%(4/21);无肿瘤家族史者共313例,AA基因型频率为11.2%(35/313),GA+GG基因型频率为88.8%(278/313),GG基因型频率为47.3%(148/313).结论 (1)CAPN-10基因SNP-56与PCOS的遗传易感性无明显相关性,但与PCOS患者糖、脂代谢异常有明显相关性.(2)CAPN-10基因SNP-56与PCOS患者糖尿病家族史及肿瘤家族史相关,应重视对高危PCOS个体的随访.     

CYP1A1基因MspⅠ位点和SULT1A1基因Arg213His位点多态性与子宫肌瘤的关联性研究

目的 探讨细胞色素P450(cytochrome P450,CYP)1A1基因MspⅠ位点和硫酸氨基转移酶(sulfotransferase,SULT)1A1基因Arg213His位点多态性与鲁北地区汉族女性子宫肌瘤的关系.方法 采用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)方法检测123例子宫肌瘤患者和123例健康对照组的CYP1A1基因MspⅠ位点的基因型和SULT1A1基因Arg213His位点的基因型,分析基因多态性与子宫肌瘤的关系.结果 子宫肌瘤组CYP1A1基因MspⅠ位点的基因型与对照组中的分布比较,差异无统计学意义(P=0.927);而子宫肌瘤组SULT1A1基因Arg213His位点的基因型与对照组中的分布比较,差异有统计学意义(P=0.011).CYP1A1基因MspⅠ位点和SULT1A1基因Arg213His位点多态性在子宫肌瘤的发生过程中的交互作用比较,差异有统计学意义(P=0.024).结论 CYP1A1基因MspⅠ位点多态性与鲁北地区汉族女性子宫肌瘤的易感性无显著相关;SULT1A1基因Arg213His位点多态性与鲁北地区汉族女性子宫肌瘤的发生有关,并增加了子宫肌瘤的患病风险;CYP1A1基因MspⅠ位点和SULT1A1基因Arg213His位点多态性在子宫肌瘤的发生过程中具有交互作用.     

胆固醇酯转运蛋白基因多态性在多囊卵巢综合征中的初步研究

目的:探讨胆固醇酯转运蛋白(CETP)在PCOS患者中的基因多态性和血脂、性激素的关系,以进一步认识PCOS脂代谢的特点。方法:应用PCR酶切方法检测108例PCOS患者及60例对照组的CETPTaqIB位点基因多态性。结果:CETPTaqIB基因频率及基因型分布在两组间分布差异无显著性。结论:CETPTaqIB基因多态性影响PCOS患者的HDLC水平,该基因在PCOS患者分布与正常人群分布无差异性。     

CYP1A1基因多态性与子宫内膜腺癌发生的关系研究

目的研究细胞色素P4501A1(CYP1A1)基因MspI位点和Ile-Val位点多态性与子宫内膜腺癌发生的关系。方法以病例-对照研究,采用聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)方法和等位基因特异性PCR(AS-PCR)技术检测84例子宫内膜腺癌患者和66例对照者CYP1A1基因MspI位点和Ile-Val位点的多态性。结果Ile-Val三种多态基因型在对照组和子宫内膜腺癌组中的分布在显著性差异(P<0.05),其中Ile/Val和Val/Val基因型在子宫内膜腺癌组中的分布频率明显高于对照组。与Ile/Ile基因型相比,Ile/Val基因型个体发生子宫内膜腺癌的相对危险度(OR)是2.682,两者差异有统计学意义(P<0.05);而MspI位点的多态性在对照组和子宫内膜腺癌组中的分布差异无统计学意义(P>0.05)。结论CYP1A1基因第7外显子的Ile/Val基因型与子宫内膜腺癌的发生有关,可以作为子宫内膜腺癌易感人群筛查的重要指标,MspI位点多态性与子宫内膜腺癌的发生无相关性。     

A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome

A (tttta)n microsatellite polymorphism in the promoter of CYP11a gene was investigated in 201 Chinese Han women with polycystic ovary syndrome (PCOS) and 147 control women. The 6/6 genotype was defined with significant difference of CYP11a polymorphism between women with PCOS and control women, and associated with greater BMI in PCOS patients, suggesting a certain role of the six-repeat allele variant in the pathogenesis of Chinese women with PCOS.     

Common polymorphisms in the CYP1A1 and CYP11A1 genes and polycystic ovary syndrome risk: a meta-analysis and meta-regression

Aim

Increasing scientific evidences suggest that common polymorphisms in the CYP1A1 and CYP11A1 genes may contribute to the development and progression of polycystic ovary syndrome (PCOS), but many existing studies have yielded inconclusive results. The aim of this study was to perform a meta-analysis of published studies on the associations between common polymorphisms in the CYP1A1 and CYP11A1 genes and susceptibility to PCOS.

Methods

An extensive literature search for relevant studies was conducted on PubMed, Embase, Web of Science, Cochrane Library, and CBM databases from their inception through 1 June, 2013. This meta-analysis was performed using the STATA 12.0 software. The crude risk ratio (RR) with 95 % confidence interval was calculated.

Results

Thirteen case–control studies were included in this meta-analysis with a total of 1,571 PCOS cases and 1,918 healthy controls. Our meta-analysis revealed that CYP1A1 MspI (rs4646903 T > C) polymorphism may increase the risk of PCOS, especially among Caucasian populations. Furthermore, CYP11A1 microsatellite [TTTA]n repeat polymorphism also showed significant associations with increased risk of PCOS among Caucasian populations. However, there was no statistically significant association between CYP1A1 Ile462Val (rs1048943 A > G) polymorphism and PCOS risk.

Conclusion

Our meta-analysis suggests that CYP1A1 MspI and CYP11A1 microsatellite [TTTA]n repeat polymorphisms may contribute to increasing susceptibility to PCOS among Caucasian populations. Detection of common polymorphisms in the CYP1A1 and CYP11A1 genes might be promising biomarkers for the diagnosis and prognosis of PCOS.     

Haplotype analysis of VEGF gene polymorphisms in polycystic ovary syndrome

Abstract

This study evaluated the association of polymorphisms of VEGF (endothelial vascular growth factor) gene + 936C/T (rs3025039), 1154?G/A (rs 1570360) and ?2578?C/A (rs 699947) in patients with polycystic ovary syndrome (PCOS) and to perform the haplotypes formed by the alleles in the Brazilian population. A total of 110 women without PCOS and 112 women with PCOS were included in the study. Genotyping analyses were performed using the PCR-RFLP assays (rs 3025039 and rs 699947) and by allelic discrimination using the real-time PCR technique (rs 1570360). In the univariate analysis, we observed a significant difference between the groups for the polymorphism rs 1570360 and this polymorphism presented statistical differences between the groups for the recessive model (p?=?.04). The frequency of the T-G-C haplotype showed a statistically significant difference between women with PCOS and controls (p?=?.05). The ?2578?A/C polymorphism was more frequent in the control group, which may be associated with a protective characteristic for the PCOS manifestation. In the sample analysis, polymorphism rs 1570360 is associated with PCOS and the T-G-C haplotype could be associated with protective factors.     

Classic PCOS phenotype is not associated with deficiency of endogenous vitamin D and VDR gene polymorphisms rs731236 (TaqI), rs7975232 (ApaI), rs1544410 (BsmI), rs10735810 (FokI): a case–control study of lower Silesian women

Abstract

Context: The role of endogenous vitamin D and vitamin D receptor (VDR) gene polymorphism in polycystic ovary syndrome (PCOS) is still controversial.

Objective: The objective of this study was to investigate for the first time in women with “classic” PCOS phenotype and healthy controls the role of the serum endogenous vitamin D level and VDR gene polymorphisms in PCOS etiology.

Design: Ninety-two women with “classic” PCOS phenotype and 85 controls from lower Silesia with comparable body mass index (BMI) were studied. In all women the waist circumference, android/gynoid fat deposit, parameters of lipid and glucose metabolism, testosterone, free androgen index, sex hormone binding globulin (SHBG) and vitamin D were evaluated. Also, VDR gene polymorphisms rs731236, rs7975232, rs1544410 and rs10735810 were assessed.

Results: Serum vitamin D levels in both groups were comparable. Also high, comparable frequencies of hypovitaminosis and vitamin D deficiency in both groups were observed. Women with “classic” PCOS phenotype had statistically significantly higher values of all measured parameters, except serum SHBG and high-density lipoprotein (HDL)-cholesterol, which were lower. The frequency of VDR genotype polymorphism was also comparable in both groups.

Conclusions: For the first time, we show that endogenous vitamin D deficiency and VDR polymorphisms are not associated with homogeneous “classic” PCOS phenotype.     

Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess

OBJECTIVE: To determine whether frequencies of the mutations in the 21-hydroxylase (CYP21) gene and the G972R variant of the insulin receptor substrate-1 (IRS1) gene are increased in women with polycystic ovary syndrome (PCOS) and adrenal androgen (AA) excess. DESIGN: Prospective case-control study. SETTING: University reproductive endocrinology laboratory and outpatient clinic. PATIENT(S): Consecutive patients of non-Hispanic white race diagnosed with PCOS (n = 114) and healthy controls (n = 95). INTERVENTION(S): Blood and DNA sampling before hormonal therapy. MAIN OUTCOME MEASURE(S): Polycystic ovary syndrome patient and healthy control genotypes, with the CYP21 and IRS1 variants. RESULT(S): Fifty-four PCOS patients with (DHEAS >3000 ng/mL) and 55 without (DHEAS <2500 ng/mL) AA excess, respectively, were studied. Of 109 patients studied, 16 (14.7%) were found to be heterozygous carriers of mutations in the CYP21 gene. Of these 16, 10 (62.5%) had excessive AA secretion (i.e., excess DHEAS levels). Fifteen patients (13.8%) were found to be heterozygous carriers of the IRS1 variant; 9 (60.0%) of these 15 had excessive AA secretion. There were no significant differences in the allele frequency of CYP21 mutations or the IRS1 variant between PCOS patients with and without AA excess, and controls. None of the subjects were found to be homozygous carriers of CYP21 mutations or the IRS1 variant. Combined heterozygosity for CYP21 mutations and the IRS1 variant was limited to women with PCOS and excessive AA (n = 3). CONCLUSION(S): The G972R variant of the IRS1 gene might represent a modifier locus among women who are heterozygous carriers of CYP21 mutations, potentially increasing their risk of developing AA excess in PCOS. Nonetheless, this IRS1 variant and CYP21 mutations seem to play a limited role in the development of PCOS in the population studied.     

Association between the vascular endothelial growth factor gene polymorphisms and the risk of polycystic ovary syndrome in Northern Chinese women

The present study aimed to investigate whether the single nucleotide polymorphisms (SNPs) rs2010963 and rs833061 in vascular endothelial growth factor (VEGF) gene is correlated with the risk of polycystic ovary syndrome (PCOS) in Northern Chinese women, as a preliminary study. This case-control study comprised 118 women with PCOS and 130 healthy women as controls. Genotyping of the two polymorphisms within the VEGF gene 5′-untranslated region and promoter region were performed using polymerase chain reaction ligase detection reaction method. The data showed that there was a significant difference in the genotype and allele distribution of the rs2010963 polymorphism between the PCOS group and the control group (p?=?.020 and .033, respectively). The women carrying the C allele (G/C?+?C/C genotype) had a lower risk of PCOS compared with the women with G/G genotype [odds ratio (OR?=?0.55; 95% confidence interval (CI)?=?0.33–0.91]. Our study shows for the first time that the rs2010963 polymorphism may be associated with a risk of PCOS in Northern Chinese women.     

Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism

OBJECTIVE: To determine if the (tttta)(n) repeat polymorphism in the promoter region of CYP11a gene is associated with hirsutism and hyperandrogenism in women from Spain. DESIGN: Controlled clinical study. SETTING: Tertiary-care institutional hospital. PATIENT(S): Ninety-two hirsute women and 33 healthy control women. INTERVENTION(S): Basal and adrenocorticotropin-stimulated serum samples and genomic DNA extracted and purified from whole-blood samples were obtained during the follicular phase of the menstrual cycle. MAIN OUTCOME MEASURE(S): CYP11a (tttta)(n) repeat-polymorphism genotype and serum ovarian and adrenal androgen levels. RESULT(S): None of the CYP11a (tttta)(n) polymorphic alleles was associated with hirsutism. The absence of the four-repeat-units allele (4R-- genotype), which has been reported by other authors to be associated with polycystic ovary syndrome (PCOS), was found in 22.4% of the women studied here and was equally distributed among patients and controls, independently of the presence of PCOS and/or ovarian or adrenal hyperandrogenism. No differences were observed in serum hormone concentrations in 4R-- individuals as compared with subjects with at least one four-repeat-units allele. CONCLUSION(S): The (tttta)(n) repeat polymorphism in the promoter region of CYP11a does not appear to play any significant role in the pathogenesis of hirsutism and hyperandrogenism in women from Spain.